Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

phase icon View trials
by phase
cancer type icon View trials by
cancer type
target icon View trials by
therapeutic target

phase 1

NCT04148937
Advanced Solid Tumors
CD73 Inhibitor Enrolling
NCT02779751
Breast Cancer or NSCLC
CDK4 & 6 Inhibitor
NCT03770494
Advanced Solid Tumors
CDK7 Inhibitor Enrolling
NCT04603001
Advanced Hematologic Malignancies
IDH1 Inhibitor Enrolling
NCT04521686
Advanced Solid Tumors
IDH1 Inhibitor Enrolling
EMBER; NCT04188548
Breast Cancer or Endometrial Cancer
Selective ER Degrader Enrolling
NCT04557384
Advanced Solid Tumors
VEGF Receptor-2 Antagonist Enrolling
NCT02572687
Gastric Cancer, Hepatocellular Carcinoma, or NSCLC
VEGF Receptor-2 Antagonist
NCT04495478
Healthy Volunteers
VEGF Receptor-2 Antagonist Enrolling